Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novo Nordisk's acquired facility faces scrutiny over recurring contamination, incomplete investigations, and ineffective co...
Novo Nordisk unveils a $1.2 billion production facility in Denmark and finalizes Catalent acquisition, with financial and opera...
- Reuters
- Reuters
Catalent (NYSE:CTLT) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $0.05 by 360...
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised c...
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, toda...
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns ov...
